质子放疗在胶质母细胞瘤治疗中展现免疫保护优势
本研究利用GL261荷瘤及无瘤小鼠模型,比较X射线与质子全脑照射后淋巴及髓系细胞群变化。X射线照射后12小时即出现严重淋巴细胞减少(CD45+CD3+淋巴细胞等下降50%),而质子照射仅使循环淋巴细胞减少15%,且未影响髓系细胞。质子治疗所致淋巴细胞减少程度轻于X射线,机制可能涉及生物学过程而非仅减少循环淋巴细胞受照剂量。
要点
- X射线脑照射后12小时即致小鼠严重淋巴细胞减少,多种淋系细胞下降50%。
- 质子照射仅使循环淋巴细胞减少15%,且髓系细胞无变化。
- 质子照射减少颈部淋巴结CD3+CD4+ T和CD3-B220+ B细胞,但不影响脾脏。
核心结论
- 质子治疗所致淋巴细胞减少程度轻于X射线照射,机制可能涉及生物学过程而非单纯减少循环淋巴细胞受照剂量。
研究设计与样本
- 使用GL261荷瘤及无瘤小鼠模型,比较X射线与质子全脑照射后淋巴及髓系细胞群变化,通过流式细胞术评估照射体积、射束方向及淋巴细胞减少发生时序。
主要发现
- 在GB小鼠模型中观察到肿瘤及放疗诱导的淋巴细胞减少。
- 无瘤小鼠X射线照射后12小时即出现严重淋巴细胞减少,CD45+CD3+淋巴细胞、CD3+CD4+及CD3+CD8+ T细胞、CD3-B220+ B细胞、CD45+CD11b+髓系细胞、CD11b+Ly6C+单核细胞及CD11b+Ly6G+中性粒细胞下降50%。
- 髓系亚型在照射后第2天恢复,而淋巴细胞恢复呈细胞类型依赖性。
- 侧向X射线束未能改变循环淋巴细胞计数。
- X射线照射后脑、颈部淋巴结及脾脏中CD3+CD4+、CD3+CD8+ T细胞及CD3-B220+ B细胞减少。
临床怎么用
- 质子治疗可能减轻胶质母细胞瘤放疗相关淋巴细胞减少,为联合免疫治疗提供依据。
- 临床可考虑将质子治疗与免疫治疗结合,并调整方案以恢复淋巴细胞/增强抗肿瘤T细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GB) and x-ray-based radiation therapy are associated with lymphopenia, which worsens prognosis and impairs antitumor immunity. Proton therapy, with its dosimetric properties that spare healthy brain tissue, is an alternative to reduce radiotoxicity. This study examined the effects of brain irradiation with x-rays or protons on lymphopenia. METHODS AND MATERIALS: We used GL261-tumor-bearing and tumor-free mice models to evaluate various lymphoid and myeloid cell populations after brain irradiation, assessing volume of brain irradiation, beam orientation, and lymphopenia onset timing via flow cytometry. RESULTS: In the GB mouse model, both tumor- and radiation-induced lymphopenia were evidenced. Severe lymphopenia, with a 50% depletion of CD45+CD3+ lymphocytes, CD3+CD4+ and CD3+CD8+ T-cell, CD3-B220+ B cells, and CD45+CD11b+ myeloids, CD11b+Ly6C+ monocytes, and CD11b+Ly6G+ neutrophils, occurred as early as 12 hours after x-ray exposure in tumor-free mice. Myeloid subtypes recovered by day 2, whereas lymphocyte recovery was cell type dependent. The use of a lateral x-ray beam failed to alter circulating lymphocyte counts. Brain, cervical lymph nodes, and spleen immune cell quantification revealed a reduction in CD3+CD4+, CD3+CD8+ T and CD3-B220+ B cells post-x-ray exposure. Protons caused a 15% decrease in circulating lymphocytes, with no change in myeloid cells. Proton exposure also reduced CD3+CD4+ T and CD3-B220+ B cells in the cervical lymph nodes but did not affect the spleen. Plasma cytokine levels in the interleukin 1 and macrophage inflammatory protein families correlated with leucocyte changes following exposure to both particle types. CONCLUSIONS: We describe that proton therapy resulted in less lymphopenia than proton radiation, and propose that the mechanism may be related to biological processes rather than solely decreased exposure of circulating lymphocytes. This may be used to guide the incorporation of immune therapy in GB. SYNOPSIS: Understanding how brain irradiation affects circulating immunity can inform strategies to improve brain tumor treatment. This involves combining irradiation with immunotherapy and adjusting clinical protocols to restore lymphocytes/boost antitumor T cells.
引用
- Coupey J, Pham TN, Toutain J, et al. Proton Radiotherapy Offers Immune-Sparing Benefits in Glioblastoma Treatment. Int J Radiat Oncol Biol Phys. 2026. PMID: 41547377. doi:10.1016/j.ijrobp.2025.12.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。